School of Arts & Sciences, Health Psychology Program, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA.
Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
Neuropsychopharmacology. 2019 Jan;44(2):245-258. doi: 10.1038/s41386-018-0185-7. Epub 2018 Aug 21.
The 2017 American College of Neuropychopharmacology (ACNP) conference hosted a Study Group on 4 December 2017, Establishing best practice guidelines to improve the rigor, reproducibility, and transparency of the maternal immune activation (MIA) animal model of neurodevelopmental abnormalities. The goals of this session were to (a) evaluate the current literature and establish a consensus on best practices to be implemented in MIA studies, (b) identify remaining research gaps warranting additional data collection and lend to the development of evidence-based best practice design, and (c) inform the MIA research community of these findings. During this session, there was a detailed discussion on the importance of validating immunogen doses and standardizing the general design (e.g., species, immunogenic compound used, housing) of our MIA models both within and across laboratories. The consensus of the study group was that data does not currently exist to support specific evidence-based model selection or methodological recommendations due to lack of consistency in reporting, and that this issue extends to other inflammatory models of neurodevelopmental abnormalities. This launched a call to establish a reporting checklist focusing on validation, implementation, and transparency modeled on the ARRIVE Guidelines and CONSORT (scientific reporting guidelines for animal and clinical research, respectively). Here we provide a summary of the discussions in addition to a suggested checklist of reporting guidelines needed to improve the rigor and reproducibility of this valuable translational model, which can be adapted and applied to other animal models as well.
2017 年美国神经精神药理学学会（ACNP）会议于 2017 年 12 月 4 日主办了一个研究小组会议，旨在制定最佳实践指南，以提高母体免疫激活（MIA）神经发育异常动物模型的严谨性、可重复性和透明度。本次会议的目标是：（a）评估当前文献并就 MIA 研究中应实施的最佳实践达成共识；（b）确定需要额外数据收集的剩余研究空白，并有助于制定基于证据的最佳实践设计；（c）向 MIA 研究界通报这些发现。在本次会议期间，详细讨论了验证免疫原剂量和标准化 MIA 模型一般设计（例如，物种、使用的免疫原化合物、饲养）的重要性，无论是在实验室内部还是实验室之间。研究小组的共识是，由于报告缺乏一致性，目前没有数据支持特定的基于证据的模型选择或方法建议，而且这个问题也延伸到了其他神经发育异常的炎症模型。这呼吁建立一个报告清单，重点关注验证、实施和透明度，以 ARRIVE 指南和 CONSORT（分别为动物和临床研究的科学报告指南）为模型。在此，我们提供了讨论的摘要，以及一份建议的报告指南清单，以提高该有价值的转化模型的严谨性和可重复性，该清单可以适应和应用于其他动物模型。
